Page 2 - C Difficile News Today

New phase 1B data support further investigation into Adiso Therapeutic's prospective treatment.

New PUNCH CD3 analyses show patients who were treated with live fecal microbiota therapy improved their gut health at 8 weeks—which correlated with improved quality-of-life scores.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

New data presented at ACG 2023 showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.

In an interview with Amy Spallone, MD, from The University of Texas MD Anderson Cancer Center, the study investigates the effects of COVID-19 precautions on healthcare-associated infections, revealing surprising results in central line-associated bloodstream infections (CLABSIs), C difficile infections, and more.

Lumen Bioscience has been granted $16.2 million by the U.S. Department of Defense to advance its C. difficile infection (CDI) treatment.

Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent Clostridioides difficile (C Diff) infection.

Clostridioides difficile (C difficile) screening in all ICU admissions identified asymptomatic carriers and their risk for developing and/or transmitting infection.

Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing Clostridioides difficile infection.

Findings showed colonization with toxigenic C. difficile was associated with a greater risk of CDI during hospitalization than cross-transmission.